125 related articles for article (PubMed ID: 17695480)
1. Dummy run for a phase II multi-institute trial of chemoradiotherapy for unresectable pancreatic cancer: inter-observer variance in contour delineation.
Yamazaki H; Nishiyama K; Tanaka E; Koiwai K; Shikama N; Ito Y; Arahira S; Tamamoto T; Shibata T; Tamaki Y; Kodaira T; Oguchi M
Anticancer Res; 2007; 27(4C):2965-71. PubMed ID: 17695480
[TBL] [Abstract][Full Text] [Related]
2. Considerable interobserver variation in delineation of pancreatic cancer on 3DCT and 4DCT: a multi-institutional study.
Versteijne E; Gurney-Champion OJ; van der Horst A; Lens E; Kolff MW; Buijsen J; Ebrahimi G; Neelis KJ; Rasch CR; Stoker J; van Herk M; Bel A; van Tienhoven G
Radiat Oncol; 2017 Mar; 12(1):58. PubMed ID: 28335780
[TBL] [Abstract][Full Text] [Related]
3. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging (MRI) compared with computed tomography (CT) for interobserver agreement of gross tumor volume delineation in pancreatic cancer: a multi-institutional contouring study on behalf of the AIRO group for gastrointestinal cancers.
Caravatta L; Cellini F; Simoni N; Rosa C; Niespolo RM; Lupattelli M; Picardi V; Macchia G; Sainato A; Mantello G; Dionisi F; Rosetto ME; Fusco V; Navarria F; De Paoli A; Guido A; Vecchi C; Basilico R; Cianci R; Delli Pizzi A; Di Nicola M; Mattiucci GC; Valentini V; Morganti AG; Genovesi D
Acta Oncol; 2019 Apr; 58(4):439-447. PubMed ID: 30632876
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of inter-observer variability in target volume delineation on stereotactic radiotherapy treatment for pituitary adenoma and meningioma near optic tract.
Yamazaki H; Shiomi H; Tsubokura T; Kodani N; Nishimura T; Aibe N; Udono H; Nishikata M; Baba Y; Ogita M; Yamashita K; Kotsuma T
Radiat Oncol; 2011 Jan; 6():10. PubMed ID: 21272369
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
Parlak C; Topkan E; Onal C; Reyhan M; Selek U
Radiat Oncol; 2012 Mar; 7():37. PubMed ID: 22429939
[TBL] [Abstract][Full Text] [Related]
7. Addition of MRI for CT-based pancreatic tumor delineation: a feasibility study.
Gurney-Champion OJ; Versteijne E; van der Horst A; Lens E; Rütten H; Heerkens HD; Paardekooper GMRM; Berbee M; Rasch CRN; Stoker J; Engelbrecht MRW; van Herk M; Nederveen AJ; Klaassen R; van Laarhoven HWM; van Tienhoven G; Bel A
Acta Oncol; 2017 Jul; 56(7):923-930. PubMed ID: 28375667
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for MRI-based contouring of gross tumor volume and organs at risk for radiation therapy of pancreatic cancer.
Heerkens HD; Hall WA; Li XA; Knechtges P; Dalah E; Paulson ES; van den Berg CAT; Meijer GJ; Koay EJ; Crane CH; Aitken K; van Vulpen M; Erickson BA
Pract Radiat Oncol; 2017; 7(2):126-136. PubMed ID: 28089481
[TBL] [Abstract][Full Text] [Related]
9. Does Motion Assessment With 4-Dimensional Computed Tomographic Imaging for Non-Small Cell Lung Cancer Radiotherapy Improve Target Volume Coverage?
Ahmed N; Venkataraman S; Johnson K; Sutherland K; Loewen SK
Clin Med Insights Oncol; 2017; 11():1179554917698461. PubMed ID: 28469512
[TBL] [Abstract][Full Text] [Related]
10. Delineation in thoracic oncology: a prospective study of the effect of training on contour variability and dosimetric consequences.
Dewas S; Bibault JE; Blanchard P; Vautravers-Dewas C; Pointreau Y; Denis F; Brauner M; Giraud P
Radiat Oncol; 2011 Sep; 6():118. PubMed ID: 21929770
[TBL] [Abstract][Full Text] [Related]
11. Use of CD-ROM-based tool for analyzing contouring variations in involved-field radiotherapy for Stage III NSCLC.
van Sörnsen de Koste JR; Senan S; Underberg RW; Oei SS; Elshove D; Slotman BJ; Lagerwaard FJ
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):334-9. PubMed ID: 16168828
[TBL] [Abstract][Full Text] [Related]
12. The delineation of target volumes for radiotherapy of lung cancer patients.
Vorwerk H; Beckmann G; Bremer M; Degen M; Dietl B; Fietkau R; Gsänger T; Hermann RM; Alfred Herrmann MK; Höller U; van Kampen M; Körber W; Maier B; Martin T; Metz M; Richter R; Siekmeyer B; Steder M; Wagner D; Hess CF; Weiss E; Christiansen H
Radiother Oncol; 2009 Jun; 91(3):455-60. PubMed ID: 19339069
[TBL] [Abstract][Full Text] [Related]
13. Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancer.
Djärv E; Nyman J; Baumann P; Ekberg L; Høyer M; Lax I; Lewensohn R; Levin N; Lund JA; Morhed E; Ericsson SR; Traberg A; Wittgren L; Johansson KA
Acta Oncol; 2006; 45(7):973-7. PubMed ID: 16982566
[TBL] [Abstract][Full Text] [Related]
14. Definition of gross tumor volume in lung cancer: inter-observer variability.
Van de Steene J; Linthout N; de Mey J; Vinh-Hung V; Claassens C; Noppen M; Bel A; Storme G
Radiother Oncol; 2002 Jan; 62(1):37-49. PubMed ID: 11830311
[TBL] [Abstract][Full Text] [Related]
15. Utilization of PET-CT in target volume delineation for three-dimensional conformal radiotherapy in patients with non-small cell lung cancer and atelectasis.
Yin LJ; Yu XB; Ren YG; Gu GH; Ding TG; Lu Z
Multidiscip Respir Med; 2013 Mar; 8(1):21. PubMed ID: 23506629
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
[TBL] [Abstract][Full Text] [Related]
17. Volumetric modulated arc therapy for advanced pancreatic cancer.
Eppinga W; Lagerwaard F; Verbakel W; Slotman B; Senan S
Strahlenther Onkol; 2010 Jul; 186(7):382-7. PubMed ID: 20582394
[TBL] [Abstract][Full Text] [Related]
18. Perfusion magnetic resonance imaging in contouring of glioblastoma patients: Preliminary experience from a single institution.
Munshi A; Ganesh T; Gupta RK; Vaishya S; Patir R; Sarkar B; Khataniar N; Bansal K; Rastogi K; Mohanti BK
J Cancer Res Ther; 2020; 16(6):1488-1494. PubMed ID: 33342818
[TBL] [Abstract][Full Text] [Related]
19. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial.
Fokas E; Clifford C; Spezi E; Joseph G; Branagan J; Hurt C; Nixon L; Abrams R; Staffurth J; Mukherjee S
Radiother Oncol; 2015 Dec; 117(3):432-7. PubMed ID: 26328939
[TBL] [Abstract][Full Text] [Related]
20. Patterns of radiotherapy practice for pancreatic cancer in Japan: results of the Japanese Radiation Oncology Study Group (JROSG) survey.
Ogawa K; Ito Y; Karasawa K; Ogawa Y; Onishi H; Kazumoto T; Shibuya K; Shibuya H; Okuno Y; Nishino S; Ogo E; Uchida N; Karasawa K; Nemoto K; Nishimura Y;
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):743-50. PubMed ID: 19879060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
